National and Kapodistrian University of Athens Medical School, Greece
Dr. Vasiliki Fragkiadaki is a dedicated Nuclear Medicine doctor currently serving at the PET/CT Department of Iatropolis Medical Group in Argyroupoli, Greece. With a robust academic foundation from the National and Kapodistrian University of Athens, she is pursuing her PhD on biochemically recurrent prostate cancer and PET/CT imaging. Vasiliki has delivered impactful presentations and published extensively in peer-reviewed journals on nuclear medicine, oncology, and PET/CT diagnostics. She combines clinical expertise with scientific inquiry, having earned accolades for her research. Outside the hospital, she engages in artistic expression and humanitarian activities. Her dynamic presence in both academia and clinical practice reflects her commitment to advancing medical imaging, patient care, and medical education.
Profile
Orcid
🎓 Education
Dr. Fragkiadaki holds a Bachelor of Medicine from the National and Kapodistrian University of Athens (2010–2016) and specialized in Nuclear Medicine at Evangelismos General Hospital (2016–2023). She is currently pursuing a PhD focusing on PET/CT applications in biochemically recurrent prostate cancer at the same university. Her education has been complemented by international nuclear medicine courses through the European Association of Nuclear Medicine (EANM) in Nantes, France (2019) and Vienna, Austria (2024). She has also received certifications in Basic Life Support (BLS) and Advanced Trauma Life Support (ATLS), and participated in the Summer School of Physics in Zakynthos (2009). Her academic journey reflects a consistent commitment to clinical excellence, research innovation, and cross-cultural scientific exposure. This strong foundation enables her to approach complex medical imaging challenges with expertise and vision.
đź’Ľ Experience
Since December 2023, Dr. Fragkiadaki has been serving as a Nuclear Medicine Doctor at the PET/CT Department of Iatropolis Medical Group in Argyroupoli, Greece. Her prior experience includes intensive specialization training at Evangelismos General Hospital, where she honed her clinical and technical expertise in advanced diagnostic imaging, radiopharmaceutical applications, and patient management in nuclear medicine. During her academic years, she actively participated in various educational symposiums, case presentations, and collaborative studies. Her hands-on experience is marked by a detailed understanding of PET/CT imaging in oncology, particularly prostate cancer. In addition to clinical responsibilities, she has served as a scientific supervisor in student conferences and shared her knowledge through public seminars and scientific meetings. Her professional ethos blends clinical precision, patient-centric care, and research-oriented thinking, making her an asset to any multidisciplinary healthcare team.
🏆 Awards and Honors
Dr. Vasiliki Fragkiadaki received the Best Research Award at the 16th Panhellenic Congress of Nuclear Medicine (2023) for her study correlating PSA levels with PET/CT imaging metrics in biochemically recurrent prostate cancer using 18F-PSMA-1007 and 18F-choline tracers. She was also awarded an Honorable Mention in 2015 by the French Institute of Athens for her article submission in the competition titled “Imagine your job of the future – Les Rencontres Économiques.” These accolades reflect her excellence in medical research, innovative thinking, and global engagement in healthcare discourse. Her recognitions affirm her capacity to contribute meaningfully to scientific literature and foster a culture of inquiry and collaboration in nuclear medicine.
🔬 Research Focus
Dr. Fragkiadaki’s research focuses on the use of advanced PET/CT imaging in oncology, particularly in biochemically recurrent prostate cancer. Her PhD explores the correlation between serum PSA levels and imaging biomarkers like SUVmax and TMTV using radiotracers such as 18F-PSMA-1007 and 18F-choline. She has co-authored pivotal papers in international journals on this topic and participated in multicenter prospective trials comparing tracer performance. Her broader interests include radiotracer development, nuclear imaging protocols, and hybrid imaging applications in lymphoma and multiple myeloma. She actively contributes to scientific literature and has presented her findings in several academic forums, demonstrating a deep commitment to translational research that enhances diagnostic accuracy and patient care.
âś… Conclusion
Dr. Vasiliki Fragkiadaki is a highly deserving candidate for the Best Researcher Award. Her clinically impactful research, demonstrated excellence in nuclear imaging of recurrent prostate cancer, and active contributions to medical science make her a standout among her peers. With continued international engagement and expanded research leadership, she is well-positioned to make transformative contributions to nuclear medicine and oncology.
Publication
Title: Semiquantitative Analysis in PET/CT Imaging of Prostate Cancer
Year: 2025
Authors: Vasiliki Fragkiadaki, Ioannis Ntanasis-Stathopoulos, Michalis Liontos, Flora Zagouri, Meletios Dimopoulos, Maria Gavriatopoulou
Link: https://doi.org/10.3390/jcm14113828
Title: Correlation of PSA blood levels with standard uptake value maximum (SUVmax) and total metabolic tumor volume (TMTV) in 18F-PSMA-1007 and 18F-choline PET/CT in patients with biochemically recurrent prostate cancer
Year: 2024
Authors: Vasiliki Fragkiadaki, Emmanouil Panagiotidis, Evaggelia Vlontzou, Theodoros Kalathas, Anna Paschali, Charalampos Kypraios, Vasiliki Chatzipavlidou, Ioannis Datseris
Link: https://doi.org/10.1097/mnm.0000000000001881
Title: Comparison of 18F-PSMA-1007 and 18F-Choline PET/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized study
Year: 2023
Authors: Emmanouil Panagiotidis, Vasiliki Fragkiadaki, Nikolaos Papathanasiou, Charalampos Kypraios, Evangelos Liatsikos, Athanasios Klampatsas, Anna Paschali, Dimitrios Exarhos, Foteini Zarokosta, Vasiliki Chatzipavlidou et al.
Link: https://doi.org/10.1097/mnm.0000000000001770
Title: Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role
Year: 2020
Authors: Dimitrios Schizas, Aikaterini Mastoraki, Leon Naar, Diamantis I. Tsilimigras, Ioannis Katsaros, Vasiliki Fragkiadaki, Georgia-Sofia Karachaliou, Nikolaos Arkadopoulos, Theodore Liakakos, Dimitrios Moris
Link: https://doi.org/10.2174/0929867326666190712160842